paroxetine has been researched along with Chemical Dependence in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abbara, C; Briet, M; Drevin, G; Jousset, N; Picard, N | 1 |
| Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
| LeBlanc, SR; Ovanessian, MM; Parikh, SV | 1 |
| Chaslerie, A; Feuillet, F; Hardouin, JB; Jolliet, P; Pivette, J; Sébille, V; Victorri-Vigneau, C; Wainstein, L | 1 |
| Antonuccio, DO; Kapadar, K; Kohlenberg, BS; Piasecki, MP; Steinagel, GM | 1 |
| Fontanella, BJ | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Bruce, K; Israel, M; Mansour, S; Marie Parent, A; Ng Ying Kin, NM; Richardson, J; Steiger, H | 1 |
| Bertschy, G; Bondolfi, G; Golaz, J; Rachid, F | 1 |
| Gray, AM; Rafieian-Kopaei, M; Sewell, RD; Spencer, PS | 1 |
| Domino, EF; Holmes, RD; Lee, A; Markel, H | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Cook, EH; Gjerde, DK; Mason, C; Mitchell, J; Perry, BD; Unis, AS; Vincent, JG | 1 |
| Rink, J; Stein, DJ | 1 |
| Connor, KM; Davidson, JR | 1 |
| Bartel, RL; Goodhue, A; Smith, NB | 1 |
3 review(s) available for paroxetine and Chemical Dependence
| Article | Year |
|---|---|
Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use.
Topics: Adult; Anxiety Disorders; Desipramine; Humans; Naltrexone; Paroxetine; Substance-Related Disorders | 2022 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Management of posttraumatic stress disorder: diagnostic and therapeutic issues.
Topics: Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Depressive Disorder; Diagnosis, Differential; Humans; Life Change Events; Paroxetine; Psychotherapy; Psychotropic Drugs; Stress Disorders, Post-Traumatic; Substance-Related Disorders | 1999 |
3 trial(s) available for paroxetine and Chemical Dependence
| Article | Year |
|---|---|
Penetrating the blind in a study of an SSRI.
Topics: Central Nervous System Stimulants; Double-Blind Method; Humans; Methamphetamine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2002 |
Reduced density of platelet-binding sites for [3H]paroxetine in remitted bulimic women.
Topics: Adult; Antidepressive Agents, Second-Generation; Binding Sites; Blood Platelets; Bulimia; Cathartics; Diuretics; Female; Humans; Paroxetine; Psychiatric Status Rating Scales; Substance-Related Disorders; Vomiting | 2005 |
Platelet serotonin measures in adolescents with conduct disorder.
Topics: Adolescent; Adolescent Behavior; Adolescent, Institutionalized; Adult; Age of Onset; Blood Platelets; Conduct Disorder; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Social Behavior; Substance-Related Disorders | 1997 |
10 other study(ies) available for paroxetine and Chemical Dependence
| Article | Year |
|---|---|
Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Forensic Toxicology; Heterozygote; Humans; Male; Paroxetine; Pharmacogenetics; Phenotype; Risperidone; Serotonin Agents; Substance-Related Disorders; Venlafaxine Hydrochloride | 2021 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex | 2010 |
Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Bromazepam; Databases, Factual; Drug Utilization; France; Humans; Hypnotics and Sedatives; Paroxetine; Pyridines; Risk; Substance-Related Disorders; Zolpidem | 2011 |
[Social anxiety and propranolol abuse: a case study].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Female; Humans; Paroxetine; Phobic Disorders; Propranolol; Self Medication; Substance-Related Disorders | 2003 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Female; Humans; Methadone; Mood Disorders; Narcotics; Opipramol; Paroxetine; Prazepam; Psychiatric Status Rating Scales; Serotonin Syndrome; Severity of Illness Index; Substance-Related Disorders; Transcranial Magnetic Stimulation; Trazodone; Valproic Acid | 2006 |
Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning.
Topics: Analysis of Variance; Animals; Conditioning, Psychological; Disease Models, Animal; Drug Administration Schedule; Fluvoxamine; Injections, Subcutaneous; Male; Morphine; Naloxone; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Substance Withdrawal Syndrome; Substance-Related Disorders | 1995 |
LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Depressive Disorder; Drug Interactions; Female; Humans; Lysergic Acid Diethylamide; Male; Paroxetine; Recurrence; Sertraline; Substance-Related Disorders; Syndrome | 1994 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Effects of "Ecstasy" blocked by serotonin reuptake inhibitors.
Topics: Adult; Citalopram; Female; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Trichotillomania | 1999 |
Exacerbation of psychosis by phenylpropanolamine.
Topics: Adult; Female; Hallucinations; Humans; Methamphetamine; Nasal Decongestants; Paranoid Disorders; Paroxetine; Perphenazine; Phenylpropanolamine; Psychoses, Substance-Induced; Recurrence; Substance-Related Disorders | 2000 |